ClinicalTrials.gg
CompletedNCT02972268Updated Aug 29, 2019

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

A Phase 3 interventional study of Tamsulosin 0.2mg + Solifenacin 5mg and Tamsulosin 0.2mg + Placebo(Solifenacin) in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2019-08-29.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2016, registered Nov 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms — 5 open to participants now, 5 under way, none of them phase 3. Tamsulosin · Lower Urinary Tract Symptoms.

Enrollment
5th of 22
780 · median 136
Started
2016
with 1 other
Phase 3
3 of 22
none open now
Registered
11th of 22
by date

Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 3, and was the 11th registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

5 of the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, or all of them as a file.
02

Study summary

Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

03

Conditions studied

  • Lower Urinary Tract Symptoms
  • Benign Prostatic Hyperplasia
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 45 years
  • Benign Prostate Hyperplasia diagnosed by 20 mL \< TRUS
  • Lower urinary tract symptom suggestive of benign prostate hyperplasia, who spontaneously agree to join and sign to the consent form

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a history of the lower urinary tract cancer, including prostate cancer and bladder cancer within the past 3 years
  • Subjects who have acute urinary retention within 12 weeks before screening
  • Subjects who have severe cardiovascular disease(unstable angina, myocardial infarction or arrhythmia) within 24 weeks before screening
  • Subjects who have to product
  • Subjects who were suspected or confirmed neurogenic bladder, bladder neck structure, bladder diverticulum
  • Subjects who have myasthenia gravis, narrow angle glaucoma
  • Subjects who have hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • SBP > 180 mmHg or DBP > 100 mmHg
  • > 9.0 %
  • Subjects who are judged by the investigators to be unsuitable to participate in the clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
780 participants (actual)

Study arms

  • Experimental
    Group I

    Tamsulosin 0.2mg + Solifenacin 5mg

    Drug: Tamsulosin 0.2mg + Solifenacin 5mg

  • Placebo comparator
    Group II

    Tamsulosin 0.2mg + Placebo(Solifenacin)

    Drug: Tamsulosin 0.2mg + Placebo(Solifenacin)

Interventions

  • DrugTamsulosin 0.2mg + Solifenacin 5mg

    Drug page: Tamsulosin

    Tamsulosin 0.2mg + Solifenacin 5mg for 12wks

  • DrugTamsulosin 0.2mg + Placebo(Solifenacin)

    Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks

06

What researchers measure

Primary outcomes

  1. change of TUFS

    Time frame: 12 weeks from baseline

  2. change of total IPSS

    Time frame: 12 weeks from baseline

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Nov 2017, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 23, 2016
StartActual
Feb 1, 2016
Primary completionActual
Nov 2, 2017
CompletionActual
Aug 14, 2018
Last update
Aug 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02972268
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Feb 1, 2016
Primary completion
Nov 2, 2017
Completion
Aug 14, 2018
Last update
Aug 29, 2019

Study contacts

Myung Soo Choo, MD., Ph.D
study chair · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion